Engineers Gate Manager’s Ocular Therapeutix OCUL Stock Holding History

Engineers Gate Manager’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$401K	Buy	+40,800	New	+$370K	0.01%	1633
2026 Q1	–	Sell	-154,969	Closed	-$1.88M	–	2445
2025 Q4	$1.88M	Buy	154,969 +127,710	+469%	+$1.55M	0.02%	736
2025 Q3	$319K	Buy	+27,259	New	+$326K	﹤0.01%	1720
2023 Q3	–	Sell	-47,760	Closed	-$246K	–	1992
2023 Q2	$246K	Buy	47,760 +28,836	+152%	+$171K	0.01%	1387
2023 Q1	$99.7K	Buy	+18,924	New	+$89.9K	﹤0.01%	1508
2021 Q3	–	Sell	-13,816	Closed	-$196K	–	1873
2021 Q2	$196K	Sell	13,816 -5,909	-30%	-$89.8K	0.01%	1412
2021 Q1	$324K	Sell	19,725 -13,266	-40%	-$256K	0.02%	1270
2020 Q4	$683K	Buy	+32,991	New	+$490K	0.03%	783

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Engineers Gate Manager's OCUL Position: Q2 2026 in Review

Engineers Gate Manager opened a new position in Ocular Therapeutix (OCUL) in Q2 2026: 40,800 shares worth $401K. The stake represents 0.01% of the portfolio and ranks #1633 among its holdings. This is a return to the name: Engineers Gate Manager previously reported a position in OCUL as recently as Q4 2025.

Engineers Gate Manager first reported a position in OCUL in Q4 2020 and has held it in 8 quarters since. The position peaked at $1.88M in Q4 2025. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Engineers Gate Manager held 40,800 shares of Ocular Therapeutix worth $401K as of Q2 2026.
Ocular Therapeutix was a new Engineers Gate Manager position in Q2 2026.
Ocular Therapeutix made up 0.01% of Engineers Gate Manager's portfolio in Q2 2026, its #1633 holding.
Engineers Gate Manager first reported a position in Ocular Therapeutix in Q4 2020 and has held it in 8 quarters since.
Engineers Gate Manager's Ocular Therapeutix position peaked at $1.88M in Q4 2025.
263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.